Answers are grounded in this paper and cite their sources.
In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).
No takes yet. Share an insight, caveat, or question.
Cosman et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: